Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species-Reference-Cited by-同舟云学术

Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species

Published:2011-06-23 Issue:1 Volume:69 Page:229-237
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kumar Vipul,Schuck Edgar L.,Pelletier Robert D.,Farah Nadia,Condon Krista B.,Ye Meng,Rowbottom Christopher,King Belinda M.,Zhang Zhi-Yi,Saxton Philip L.,Wong Y. Nancy

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-011-1687-8.pdf

Reference19 articles.

1. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA (2003) The conduct of in vitro and in vivo drug–drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815–832

2. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature. ;417(6892):949–954

3. Ellestad GA, Lovell FM, Perkinson NA, Hargreaves RT, McGahren WJ (1978) New zearalenone related macrolides and isocoumarins from an unidentified fungus. J Org Chem 43:2339–2343

4. Gabrielsson J, Weiner D (2000) Pharmacokinetic and pharmacodynamic data analysis. Swedish pharmaceutical press, Stockholm, Sweden

5. Goto M, Chow J, Muramoto K, Chiba K, Yamamoto S, Fujita M, Obaishi H, Tai K, Mizui Y, Tanaka I, Young D, Yang H, Wang YJ, Shirota H, Gusovsky F (2009) E6201 [(3S, 4R, 5Z, 8S, 9S, 11E)-14-(ethylamino)-8, 9, 16-trihydroxy-3, 4-dimethyl-3, 4, 9, 19-tetrahydro-1H–2-benzoxacyclotetradecine-1, 7(8H)-dione], a novel kinase inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK)-1 and MEK kinase-1: In vitro characterization of its anti-inflammatory and antihyperproliferative activities. J Pharmacol Exp Ther 331(2):485–495

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metabolic stability and its role in the discovery of new chemical entities;Acta Pharmaceutica;2019-06-26

2. Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study;British Journal of Cancer;2018-06

3. The Cysteinome of Protein Kinases as a Target in Drug Development;Angewandte Chemie International Edition;2018-02-02

4. Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung;Angewandte Chemie;2018-02-02

5. Targeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug Discovery;Current Topics in Medicinal Chemistry;2016-11-14